載入中
NASDAQHealthcareBiotechnology
最新資料
US$37.22
+US$2.61 · +7.54%
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
前收盤價
US$37.22
+US$2.61 · +7.54%
盤中時間採用ET。市場資料可能有所延遲。
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
日內區間
目前US$37.22
52週區間
目前US$37.22
盤中時間採用ET。市場資料可能有所延遲。
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
日內區間
目前US$37.22
52週區間
目前US$37.22
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 研究與開發 | 1674.4萬 USD | 5117.1萬 USD | 784.5萬 USD | 134.6萬 USD |
| 銷售、一般及管理費用 | 1366萬 USD | 1365.9萬 USD | 353.1萬 USD | 146.3萬 USD |
| 營業費用 | 3040.4萬 USD | 6483萬 USD | 1137.6萬 USD | 280.9萬 USD |
| 利息收入 | 392萬 USD | 172.1萬 USD | 81.1萬 USD | 7.3萬 USD |
| 利息支出 | — | — | 482.5萬 USD | 215.1萬 USD |
| 折舊和攤銷 | 32.1萬 USD | 9.1萬 USD | 4000 USD | 2000 USD |
| 營業利益 | −3040.4萬 USD | −6483萬 USD | −1137.6萬 USD | −280.9萬 USD |
| 淨利 | −2520.5萬 USD | −6310.2萬 USD | −627.5萬 USD | −1434.8萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$59.78
上漲空間 60.61%評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3232.63萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2046.98萬0.03%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1336.91萬0.01%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO607.49萬0.03%180億 USD0.06%US$112.66+0.50%
State Street SPDR S&P Pharmaceuticals ETFXPH586.82萬1.27%4.62億 USD0.35%US$64.65+1.60%
Schwab U.S. Small-Cap ETFSCHA465.3萬0.02%218.24億 USD0.03%US$32.79+0.40%
iShares Russell 2000 Growth ETFIWO343.8萬0.02%139.17億 USD0.24%US$356.78+0.94%
iShares U.S. Pharmaceuticals ETFIHE303.29萬0.20%15.52億 USD0.37%US$100.09+1.24%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOiShares U.S. Pharmaceuticals ETFIHEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
